SIOUX FALLS, SD--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully-human polyclonal antibodies, today announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will participate in a fireside chat at the RBC Capital Markets 2021 Global Healthcare Conference on Thursday, May 20, 2021 at 11:30 a.m. ET.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, specifically-targeted, high-potency, human polyclonal immunotherapies at commercial scale. In addition to COVID-19, the company’s pipeline also includes programs in Type 1 diabetes, organ transplant, influenza and a human immune globulin (IgG) to treat autoimmune diseases. For more information visit: www.sabbiotherapeutics.com or follow @SABBantibody on Twitter.